Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 8/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.51 |
| ▸ | CDK2 | P24941 | 5/20 | 0.51 |
| ▸ | AHCY | P23526 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.34 |
| ▸ | HINT1 | P49773 | 1/20 | 0.33 |
| ▸ | PI4KA | P42356 | 2/20 | 0.32 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.32 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24499765 | 0.75 | CDK1 (0.56) | CDK1CCNB1CCNE1CDK2AHCY | |
| SCHEMBL24239210 | 0.72 | CDK1 (0.53) | CDK1CCNB1CCNE1CDK2AHCY | |
| SCHEMBL20460821 | 0.72 | CDK1 (0.56) | CDK1CCNB1CCNE1CDK2AHCY | |
| SCHEMBL129642 | 0.72 | CDK1 (0.68) | CDK1CCNB1CCNE1CDK2AHCY | |
| SCHEMBL27983442 | 0.71 | CDK1 (0.59) | CDK1CCNB1CCNE1CDK2AHCY | |
| SCHEMBL21539217 | 0.70 | CDK1 (0.71) | CDK1CCNB1CCNE1CDK2AHCY | |
| SCHEMBL6510998 | 0.70 | CDK1 (0.58) | CDK1CCNB1CCNE1CDK2AHCY | |
| SCHEMBL3964706 | 0.69 | CDK1 (0.57) | CDK1CCNB1CCNE1CDK2AHCY | |
| SCHEMBL23866997 | 0.69 | XDH (0.36) | — | |
| SCHEMBL7660090 | 0.68 | CDK1 (0.56) | CDK1CCNB1CCNE1CDK2AHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | CDK1 1548/4885CCNB1 2850/4885CCNE1 2505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.